Samsara BioCapital LLC purchased a new position in Alumis Inc. (NASDAQ:ALMS - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 3,266,498 shares of the company's stock, valued at approximately $34,886,000. Alumis makes up 6.7% of Samsara BioCapital LLC's holdings, making the stock its 5th largest holding. Samsara BioCapital LLC owned 6.92% of Alumis as of its most recent SEC filing.
Several other large investors have also made changes to their positions in ALMS. BNP Paribas Financial Markets purchased a new position in shares of Alumis during the third quarter valued at approximately $27,000. MetLife Investment Management LLC purchased a new position in Alumis during the 3rd quarter valued at $89,000. Maven Securities LTD purchased a new stake in Alumis in the second quarter worth $332,000. Towerview LLC lifted its holdings in Alumis by 22.6% during the 3rd quarter. Towerview LLC now owns 380,000 shares of the company's stock valued at $4,058,000 after buying an additional 70,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. purchased a new position in Alumis during the 3rd quarter worth $1,160,000.
Alumis Stock Up 7.6 %
Shares of Alumis stock traded up $0.61 during midday trading on Thursday, hitting $8.60. The company had a trading volume of 230,156 shares, compared to its average volume of 149,790. Alumis Inc. has a 12-month low of $7.66 and a 12-month high of $13.53. The business has a fifty day moving average price of $10.67.
Analysts Set New Price Targets
Several equities analysts have recently commented on ALMS shares. HC Wainwright cut their price target on Alumis from $30.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday, November 14th. Cantor Fitzgerald restated an "overweight" rating on shares of Alumis in a report on Thursday, November 14th. Robert W. Baird started coverage on shares of Alumis in a research note on Thursday, October 31st. They set an "outperform" rating and a $25.00 price objective on the stock. Finally, Baird R W raised shares of Alumis to a "strong-buy" rating in a research note on Thursday, October 31st. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $26.83.
Check Out Our Latest Research Report on ALMS
Alumis Profile
(
Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
See Also
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
